📊 Midday Market Take

Happy Friday, and markets are giving us something to smile about this afternoon, with the S&P 500 up 0.28%, the Nasdaq gaining 0.30%, and the Dow adding 0.19%. It is a quiet but steady green day across the board, nothing flashy, just the kind of calm drift higher that long-term investors actually love.

Tech is the sector worth keeping your eye on right now, as the Nasdaq's modest lead over the other indices suggests money is quietly rotating back into growth names. If that trend holds into the close, you might want to check your exposure to large-cap tech, because a Friday finish in the green there tends to set a confident tone for the week ahead.

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.

3 Reasons to Watch SLS

• Three Straight Days of Explosive Moves. SLS has posted notable gains on Wednesday, Thursday, and Friday, with multiple news outlets covering what's driving each leg higher. When a small-cap biotech gets this kind of sustained attention across consecutive sessions, it signals something more than a one-day pop worth monitoring.
• A 14% Single-Day Jump Caps a Wild Month. The most recent session closed at $12.04, up 14.29%, capping a 30-day run of over 62%. That kind of momentum in a late-stage clinical name means traders and longer-term investors are both paying close attention to what comes next.
• 217% in 90 Days Is Hard to Ignore. SLS has gained more than 217% over the past three months and nearly 493% over the past year, which puts it in rare company for a clinical-stage biotech. With its lead cancer immunotherapy candidate GPS and a collaboration with Merck still in the mix, the question heading into the next session is whether the fundamentals are starting to catch up with the price action.

Top Market Headlines

Are Industrial Products Stocks Lagging Caterpillar (CAT) This Year?

Here is how Caterpillar (CAT) and Kaiser Aluminum (KALU) have performed compared to their sector so far this year.

After "33X" call, Hall of Fame Trader Jon Najarian reveals NEW Tesla prediction (Ad)

Jon Najarian put his neck out on national TV for Tesla in 2014… Before Tesla stock flew to peak gains of 3,392% today! But this "33X" call on Tesla might pale in comparison to Jon's newest prediction about Elon Musk… That a potential $44 TRILLION plan could be coming next.

Memory chip stocks are on fire again: MU, SNDK, WDC, and STX soar as Micron earnings stun Wall Street

Shares in the four most prominent memory chip makers are once again surging this morning.

Apple, Sandisk, Marvell, and More Stocks That Explain Today's Market

Tech looks set to extend a recent slump as Wall Street dumps some of the stocks that have benefited most from the AI trading frenzy.

Is Elon about to trigger another 315X opportunity? (Ad)

Elon gave Tesla investors the chance to make more than 315 times their money when he revived the electric vehicle industry. $1 billion fund manager Louis Navellier believes Elon's "Project Apex" will mint a new generation of millionaires.

3 Top Stocks to Buy With $3,000 Right Now

Market data and ratings outfit S&P Global is reshaping itself into something even more promising, even if the stock doesn't yet indicate it.

Iran just proved America's energy strategy is broken (Ad)

When the U.S.-Iran deal allowed Iranian oil back into the market, prices fell immediately and energy stocks dropped 1.7%. That's not stability - that's a supply hostage situation repeating since 1973. Beneath American soil sits an energy source 50,000 times larger than all global oil and gas...